Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Diffusion-Model-Guided Identification of a Candidate α-Synuclein Aggregation Inhibitor under Secondary-Nucleation-Dominated Conditions.

Created on 12 Nov 2026

Authors

Hao Zhang, Robert I Horne, Z Faidon Brotzakis, Charles Harris, Pietro Liò, Michele Vendruscolo

Published in

The journal of physical chemistry letters. Volume 17. Issue 45. Pages 12864-12870. Nov 12, 2026.

Abstract

The process of α-synuclein aggregation results in the formation of amyloid deposits that accumulate in the brain of patients affected by Parkinson's disease and related synucleinopathies. Among possible therapeutic strategies for these conditions, one approach is based on the development of compounds capable of inhibiting α-synuclein aggregation. An effective inhibition could be achieved by blocking the nucleation sites on the surface of the amyloid fibrils that are responsible for their autocatalytic proliferation. Here, we use an E(3)-equivariant conditional diffusion model to identify candidate inhibitors of this type. With this approach, we generated pocket-conditioned molecules, identified purchasable analogues, and experimentally tested selected compounds. We thus identified a compound that delays α-synuclein aggregation under conditions in which secondary nucleation is the dominant process. These results illustrate the use of conditional diffusion models to identify candidate aggregation inhibitors.

PMID:
43018333
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement